| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Martini Hospital, Groningen, The Netherlands. 2 Birmingham Heartlands Hospital, Birmingham, UK. 3 Bispebjerg Hospital, Copenhagen, Denmark. 4 UZ Gasthuisberg, Leuven, Belgium. 5 Humana Medical Centre, Sandvika, Norway. 6 Semmelweis University, Budapest, Hungary. 7 Dept of Internal Medicine and Allergology, Wroclaw Medical Hospital, Wroclaw, Poland. 8 The Queen Elizabeth Hospital, Woodville South, Australia. 9 Medical Hospital and Health Centre, Homburg, Germany
CORRESPONDENCE: G.W. Sybrecht, Medizinische Universitätskliniken, Inner Medizin V, D-66241, Homburg, Germany. Fax: 49 68411623602. E-mail: pngsyb@uniklinik-saarland.de
Keywords: bronchodilation, chronic obstructive pulmonary disease, formoterol
Received: April 27, 2001
Accepted January 9, 2002
This study was supported by AstraZeneca
The aim of this study was to investigate formoterol, an inhaled long-acting ß2-agonist, in patients with chronic obstructive pulmonary disease (COPD).
Six-hundred and ninety-two COPD patients, mean baseline forced expiratory volume in one second (FEV1) 54%, FEV1/forced vital capacity 75% of predicted, reversibility 6.4% pred, were treated with formoterol (4.5, 9 or 18 µg b.i.d.) or placebo via Turbuhaler® for 12 weeks. Symptoms were recorded daily. Spirometry and the incremental shuttle walking test (SWT) were performed at clinic visits.
Compared with placebo, 18 µg b.i.d. formoterol reduced the mean total symptom score by 13% and increased the percentage of nights without awakenings by 15%. Formoterol (9 and 18 µg b.i.d.) significantly reduced symptom scores for breathlessness (–7% and –9%, respectively) and chest tightness (–11% and –8%, respectively), reduced the need for rescue medication (–25% and –18%, respectively), and increased symptom-free days (71% and 86%, respectively). FEV1 improved significantly after all three doses of formoterol (versus placebo). No differences were found between groups in SWT walking distance. No unexpected adverse events were seen.
In conclusion, 9 and 18 µg b.i.d. formoterol reduced symptoms and increased the number of symptom-free days in a dose-dependent manner in chronic obstructive pulmonary disease patients. Formoterol improved lung function at a dose of 4.5 µg b.i.d. and higher.
This article has been cited by other articles:
|
|
 |
|
  J. F. Donohue, N. A. Hanania, C. Fogarty, S. C. Campbell, M. Rinehart, and K. Denis-Mize Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 199 - 208. [Abstract] [PDF]
|
|
|
|
 |
|
 P. T. Diaz, A. S. Bruns, M. E. Ezzie, N. Marchetti, and B. M. Thomashow Optimizing Bronchodilator Therapy in Emphysema Proceedings of the ATS, May 1, 2008; 5(4): 501 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Rodrigo, L. J. Nannini, and R. Rodriguez-Roisin Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review Chest, May 1, 2008; 133(5): 1079 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S D Aaron, D Fergusson, G B Marks, S Suissa, K L Vandemheen, S Doucette, F Maltais, J F Bourbeau, R S Goldstein, M Balter, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials Thorax, February 1, 2008; 63(2): 122 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Wilt, D. Niewoehner, R. MacDonald, and R. L. Kane Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline Ann Intern Med, November 6, 2007; 147(9): 639 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. O'Donnell Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance Eur. Respir. Rev., December 1, 2006; 15(99): 37 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Decramer Tiotropium as essential maintenance therapy in COPD Eur. Respir. Rev., December 1, 2006; 15(99): 51 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Rabe Improving Dyspnea in Chronic Obstructive Pulmonary Disease: Optimal Treatment Strategies Proceedings of the ATS, May 1, 2006; 3(3): 270 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Scott, P Walker, and P M A Calverley COPD exacerbations {middle dot} 4: Prevention Thorax, May 1, 2006; 61(5): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-Y. Chen, K.-Y. Yang, Y.-C. Lee, and P.-P. Perng Effect of Oral Aminophylline on Pulmonary Function Improvement and Tolerability in Different Age Groups of COPD Patients Chest, October 1, 2005; 128(4): 2088 - 2092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. van Noord, J-L. Aumann, E. Janssens, J. J. Smeets, J. Verhaert, B. Disse, A. Mueller, and P. J. G. Cornelissen Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD Eur. Respir. J., August 1, 2005; 26(2): 214 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E F M Wouters, D S Postma, B Fokkens, W C J Hop, J Prins, A F Kuipers, H R Pasma, C A J Hensing, E C Creutzberg, and for the COSMIC (COPD and Seretide: a Multi-Center Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial Thorax, June 1, 2005; 60(6): 480 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. van der Woude, J. Zaagsma, D. S. Postma, T. H. Winter, M. van Hulst, and R. Aalbers Detrimental Effects of {beta}-Blockers in COPD: A Concern for Nonselective {beta}-Blockers Chest, March 1, 2005; 127(3): 818 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mahler, S. Huang, M. Tabrizi, and G. M. Bell Efficacy and Safety of a Monoclonal Antibody Recognizing Interleukin-8 in COPD: A Pilot Study Chest, September 1, 2004; 126(3): 926 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Sutherland and R. M. Cherniack Management of Chronic Obstructive Pulmonary Disease N. Engl. J. Med., June 24, 2004; 350(26): 2689 - 2697. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter Cardiovascular Effects of {beta}-Agonists in Patients With Asthma and COPD: A Meta-Analysis Chest, June 1, 2004; 125(6): 2309 - 2321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B J Smith, S L Appleton, A J Veale, H J McElroy, D Veljkovic, and L Saccoia Eformoterol n-of-1 trials in chronic obstructive pulmonary disease poorly reversible to salbutamol Chronic Respiratory Disease, April 1, 2004; 1(2): 63 - 69. [Abstract] [PDF]
|
|
|
|
|
|
D. P. Tashkin and C. B. Cooper The Role of Long-Acting Bronchodilators in the Management of Stable COPD Chest, January 1, 2004; 125(1): 249 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Sin, F. A. McAlister, S. F. P. Man, and N. R. Anthonisen Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review JAMA, November 5, 2003; 290(17): 2301 - 2312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Szafranski, A. Cukier, A. Ramirez, G. Menga, R. Sansores, S. Nahabedian, S. Peterson, and H. Olsson Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur. Respir. J., January 1, 2003; 21(1): 74 - 81. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
